Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Chou Associates REALLY Loves Its Portfolio, Because It Didn’t Touch It Last Quarter

Page 1 of 2

Chou Associates Management Inc. aims to provide long term growth of capital. The fund mainly invests in the US securities and has fairly diversified portfolio. Finance stocks form 33% of the portfolio followed by Health Care stocks forming 19%. Consumer discretionary stocks account for 12% of its holding. The investment fund invests in common and preferred stock as well as in convertible debentures and corporate bonds.

Chou Associates Fund has offered compounded annual return of 7.5% over the course of past five years. This article will discuss some of the stocks held by Chou Associates Management and their overall outlook. These stocks are Valeant Pharmaceuticals Intl Inc. (NYSE:VRX), Berkshire Hathaway Inc. (NYSE:BRK.A), Resolute Forest Products Inc. (NYSE:RFP), Nokia Corp (ADR) (NYSE:NOK) and Citigroup Inc. (NYSE:C).

The smart money sentiment is an important metric that can be used to assess the long-term profitability of a stock. While there are thousands of stocks trading daily on the market, taking a look at what hedge funds think about certain companies can narrow down the search significantly. At Insider Monkey, we track more than 700 hedge funds, whose 13F filings we analyze as part of our small-cap strategy. Our research has shown that imitating a portfolio that includes the 15 most popular small-cap stocks among hedge funds can outperform the market by as much as 95 basis points per month on average (see more details here).

finance, stock, trade, market, data, graph, money, risk, building, chart, sell, bank, banking, display, accounting, business, price, board, index, success, wealth, blue,

crystal51/Shutterstock.com

Valeant Pharmaceuticals Intl Inc. (NYSE:VRX) stock dipped 76% this year so far. However, the stock accounted for 13.14% of the portfolio. For the quarter ended on 30th September, 2016, the investment fund held 1.44 million shares of Valeant amounting to $35.52 million. Of the hedge funds in our database, 60 funds currently hold $2.11 billion worth of Valeant shares in their portfolio at the end of the June quarter, which equals to 30.80% of the outstanding shares. Valeant is said to be mulling the sale of Salix Pharmaceuticals to Takeda, Japan’s largest pharmaceuticals group. The deal is potentially likely to be worth $10 billion. Valeant had acquired Salix less than two years back. However, no other details of the probable deal have been provided.

Follow Valeant Pharmaceuticals International (NYSE:VRX)
Trade (NYSE:VRX) Now!

Berkshire Hathaway Inc. (NYSE:BRK.A) stock gained 7% in this year so far. Chou Associates Management held $32.43 million worth of Berkshire Hathaway stock at the end of the September quarter, forming 12% of its portfolio. Chou Associates Management had 150 shares of the company in its portfolio at the end of the period. Among the funds we track, 78 funds held $19.43 billion worth of Berkshire Hathaway’s stock in aggregate at the end of June, having amassed 5.4% of its outstanding stock. One of Berkshire’s top positions is Wells Fargo, which is currently embroiled in various controversies including fake accounts.Wells Fargo also saw the departure of its CEO in the wake of the scandal. Berkshire currently owns 10% stake in the bank.

Follow Berkshire Hathaway Inc (NYSE:BRK.A)
Trade (NYSE:BRK.A) Now!
Page 1 of 2
Loading Comments...